| Detected | Trial | Change |
|---|---|---|
| 2026-08-02 | NCT05739045 Nivolumab Combined With SOX Used in the Perioperative Treatment |
overall status: Recruiting → Unknown |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07068516 | Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive… | Gastric Cancer Stage | Not Yet Recruiting |
| Phase 2 | |||
| NCT06374901 | Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. | Gastric Cancer | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT06766305 | QL1706 Combined With SOX Used in Theperioperative Treatment | Gastric Cancers | Recruiting |
| Phase 1 | |||
| NCT06610799 | Study of IBI363 in Patients with Advanced First-line Gastric Cancer | IBI363 + Chemotherapy | Recruiting |
| Not specified | |||
| NCT06614179 | A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established | Abdominal Neoplasm | Recruiting |
| NCT06642857 | Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with… | Advanced Gastric Carcinoma | Recruiting |